Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma
- 1 July 2005
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (13), 4818-4826
- https://doi.org/10.1158/1078-0432.ccr-04-2330
Abstract
Purpose: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is expressed on 95% of colorectal cancers. A previous study has shown excellent tumor-targeting of iodine-131 labeled huA33 (131I-huA33). Therefore, we did a phase I dose escalation trial of 131I-huA33 radioimmunotherapy. Experimental Designs: Fifteen patients with pretreated metastatic colorectal carcinoma each received two i.v. doses of 131I-huA33. The first was an outpatient trace-labeled “scout” dose for biodistribution assessment, followed by a second “therapy” dose. Three patients were treated at 20, 30, and 40 mCi/m2 dose levels, and six patients at 50 mCi/m2 to define the maximum tolerated dose. Results: Hematologic toxicity was 131I dose-dependent, with one episode of grade 4 neutropenia and two episodes of grade 3 thrombocytopenia observed at 50 mCi/m2. The maximum tolerated dose was determined to be 40 mCi/m2. There were no acute infusion-related adverse events, and gastrointestinal toxicity was not observed despite uptake of 131I-huA33 in bowel. Seven patients developed pruritus or rash, which was not related to 131I dose. There was excellent tumor-targeting of 131I-huA33 shown in all patients. The serum T1/2β of 131I-huA33 was (mean ± SD) 135.2 ± 46.9 hours. The mean absorbed tumor dose was 6.49 ± 2.47 Gy/GBq. Four patients developed human anti-human antibodies. At restaging, 4 patients had stable disease, whereas 11 patients had progressive disease. Conclusion: Radioimmunotherapy using 131I-huA33 shows promise in targeting colorectal tumors, and is deliverable at a maximum tolerated dose of 40 mCi/m2. Further studies of 131I-huA33 in combination with chemotherapy are planned.Keywords
This publication has 20 references indexed in Scilit:
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Phase I Radioimmunotherapy Trial with Iodine-131—Labeled Humanized MN-14 Anti—Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal CancerClinical Colorectal Cancer, 2002
- Radioimmunotherapy of small-volume disease of metastatic colorectal cancerCancer, 2002
- Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III StudyJournal of Clinical Oncology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Characterization of Posttranslational Modifications of Human A33 Antigen, a Novel Palmitoylated Surface Glycoprotein of Human Gastrointestinal EpitheliumBiochemical and Biophysical Research Communications, 1997
- The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamilyProceedings of the National Academy of Sciences of the United States of America, 1997
- A CT assisted method for absolute quantitation of internal radioactivityMedical Physics, 1996
- Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodiesNuclear Medicine Communications, 1996
- Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (taxol®)International Journal of Radiation Oncology*Biology*Physics, 1994